Mark DeLong - May 18, 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Senior Vice President
Signature: /s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol: APLS
Transactions as of: May 18, 2021
Transactions value $: -$78,960
Form type: 4
Date filed: 5/19/2021, 04:04 PM
Next filing: Jun 16, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$31K	+2K	+21.07%	$15.52	11.5K	May 18, 2021	Direct	F1, F2
transaction	APLS	Common Stock	Sale	-$110K	-2K	-17.41%	$55.00	9.49K	May 18, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-2K	-4%	$0.00	48K	May 18, 2021	Common Stock	2K	$15.52	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise from an established 10B5-1 trading plan.
F2	This amount includes 792 shares from 04/30/2021 ESPP purchase.
F3	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.